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Functional imaging plays a growing role in the clinical assessment and research investigation of patients with epilepsy. This
article reviews the literature on functional MRI (fMRI) investigation of EEG activity, fMRI evaluation of cognitive and motor
functions, magnetic resonance spectroscopy (MRS), single photon emission computed tomography (SPECT) and positron
emission tomography (PET) in epilepsy. The place of these techniques in clinical evaluation and their contribution to a better
neurobiological understanding of epilepsy are discussed.
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INTRODUCTION
The investigation, management and scientific study
of patients with epilepsy has been transformed over
the last 15 years with the advent of increasingly
sophisticated brain imaging techniques. Prominent
amongst these, and widely used in many epilepsy
centres, are high resolution structural imaging with
magnetic resonance imaging (MRI), imaging of
cerebral metabolic rate with 18-fluorodeoxyglucose
(18FDG) positron emission tomography (PET) and
imaging of cerebral blood flow with single photon
emission computed tomography (SPECT). Many
other techniques are in occasional clinical use, are
undergoing clinical development, or have been used
in research studies, such as magnetic resonance
spectroscopy (MRS), functional magnetic resonance
imaging (fMRI) and neuroreceptor imaging studies
with both PET and SPECT. Epilepsy is particularly
challenging from an imaging point of view because
fixed abnormalities may be present (structural lesions
such as hippocampal sclerosis (HS) or malformations
of cortical development (MCD)) in addition to
transient abnormalities related to interictal EEG spikes
or seizures, which may be detected with a variety
of functional imaging techniques. Furthermore, the
presence of a focal abnormality in the brain of a patient
with epilepsy may give rise to a reorganization of
the topographical representation of cortical functions,
which may be of research interest or may be of clinical
importance when mapping essential functions prior
to resective surgery in eloquent areas. Because of
these many interesting challenges, imaging in epilepsy
encompasses the full range of currently available
imaging acquisition and analysis techniques; this brief
review attempts to provide an overview and inter-
pretation of the current state of the art in functional
imaging, both from a research and clinical standpoint.
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FUNCTIONAL IMAGING TECHNIQUES
SPECT has been the most widely used functional
imaging technique in epilepsy. Usually, a commer-
cially available compound labelled with a long-lived
radioisotope is injected intravenously and a single
image of radiotracer distribution in the brain is
obtained hours later using relatively cheap, simple
and widely available gamma-camera technology. Cost,
availability and ability to image ictal events are the
advantages of this technique; relatively low resolution,
lack of quantitation of measured parameters and
relatively limited choice of measurable variables are
the disadvantages: currently, only techniques to image
blood flow and a small number of neuroreceptors are
in general use.
PET has also been widely employed. Some of
the principles are similar to those of SPECT, but
PET relies on short-lived positron-emitting isotopes
and on simultaneous detection of pairs of photons.
Hence, an on-site cyclotron is usually required and
the detector hardware and imaging software are
vastly more expensive than for SPECT. Quantitation
and high resolution have been strengths of PET in
comparison with SPECT, although in theory there is
no reason for SPECT to be non-quantifiable or lower
resolution than PET; the difference reflects the fact
that PET has largely been a research technique in
academic centres whereas SPECT has been marketed
as a clinical technique potentially usable in a wide
range of clinical facilities. PET is scarce and costly,
but blood flow, metabolic rate and a very wide range
of receptor, enzyme and transporter parameters can be
measured accurately and with relatively high spatial
resolution. Despite this wide potential, however, most
centres only image glucose metabolism and cerebral
blood flow.
MRS requires exactly the same equipment as
conventional MRI, hence, potentially, is very widely
available. However, obtaining reliable magnetic res-
onance spectra is highly technically demanding and
MRS has remained a little-used technique in epilepsy,
confined largely to academic centres. The basic
principle is that the resonance frequency of an atomic
nucleus within an applied magnetic field is shifted
in different chemical environments, allowing concen-
trations of a variety of substances to be measured
from a magnetic resonance spectrum. Spectra may
be obtained from various nuclei, of which the most
widely used have been 1H and 31P. These spectra may
be obtained under a range of acquisition techniques,
permitting concentrations of a variety of substances
to be measured. The technical demands and very
low spatial resolution are current limiting factors; the
ability to measure many substances non-invasively
promises an exciting future.
fMRI depends on a specific MRI acquisition
technique allowing detection of signals which are
probably dependent on blood oxygenation level.
Hence, the magnitude of this signal in a particular
brain region will depend on the local neuronal
metabolic rate. Rapid image acquisition techniques
coupled with multiple image acquisitions under
different conditions allow the detection of regions with
significant change in blood oxygenation level between
these conditions (blood oxygenation-level-dependent
contrast—BOLD).
EEG-based dipole source imaging and MEG-based
magnetic source imaging are techniques allowing
interictal electrical and magnetic activity, respectively,
to be mapped into three-dimensional space, often
into an MRI volume. EEG technology is ubiquitous,
although large numbers of digitally recorded channels
are needed for transformation to useful dipole source
imaging; MEG requires extremely expensive mag-
netically shielded rooms and ultra-low temperature
detectors. The temporal resolution of these techniques
is extremely high, but spatial resolution is uncertain,
relying on assumptions about the geometry of the
head. They will not be discussed further here.
All functional imaging techniques should be inter-
preted with reference to high-quality high-resolution
MRI structural imaging; techniques to allow coreg-
istration of functional to structural imaging are
available1, as are techniques to correct for the partial
volume averaging effects of relatively low-resolution
PET and SPECT, allowing more accurate regional
parameter measurements2–8. Finally, a growing trend
is the objective, automated analysis of functional
imaging data, allowing individual patient scans to be
compared with a normal control group and significant
abnormalities in the patient to be defined in a statisti-
cally rigorous manner9–11. A novel technique permits
the simultaneous comparison of both structural and
functional imaging from the same patient with normal
controls, in order to detect areas with discordance
between structural and functional abnormalities12.
COMPARISON OF IMAGING TECHNIQUES
It is important to emphasize at the outset that structural
imaging with MRI is of paramount importance in
the routine clinical investigation of patients with
epilepsy, including pre-operative assessment. Indeed,
it is essential that any functional imaging study,
undertaken for any purpose, should be interpreted with
reference to current structural imaging. Furthermore,
the imaging literature is clouded by studies in which
imaging techniques have been compared with one
another (e.g. the sensitivity of structural MRI to detect
a putative seizure focus has often been compared with
Functional imaging in epilepsy 141
the sensitivity of 18FDG PET) without taking into
account the relative methodological development of
each technique at the time of the study—for example,
early studies comparing relatively primitive MRI with
well-developed 18FDG PET found PET to be generally
superior, whereas today this is not the case. Hence,
the role and relative utility of each imaging technique
needs to be constantly re-evaluated in the light of
current developments in imaging techniques. Even
amongst internationally renowned epilepsy surgery
centres, the extent to which functional imaging
techniques are employed is extremely variable and
may often reflect local experience in the scientific
development of particular imaging techniques rather
than a clear adherence to the evidence for their role.
The techniques of structural imaging, the impact of
this approach and its role in clinical investigation has
been extensively reviewed elsewhere13.
FUNCTIONAL MRI
fMRI has been applied in the epilepsies for a relatively
short time and the literature is not extensive. Recent
reviews of this area have been published14, 15.
Ictal and interictal epileptiform activity
For most patients with epilepsy, EEG is the most
useful technique employed to localize the seizure
focus. Interictal epileptiform activity may be detected
and ictal recordings may localize the onset of
the seizure. Although EEG generally only records
electrical potential at the scalp surface, a number
of techniques have been devised to allow a three-
dimensional reconstruction of the origin of EEG
electrical activity (source localization). These tech-
niques have a number of inherent assumptions and
disadvantages (reviewed in Ref. 16). Therefore, in the
context of pre-surgical evaluation, invasive electrode
studies are often used to add further anatomical
information. Such studies have a small but significant
morbidity, hence alternatives to this technique have
been sought in functional imaging. The transient
bursts of neural activity associated with interictal
spikes or seizures are usually accompanied by a
transient and relatively localized increase in cerebral
blood flow (CBF); fMRI permits changes in CBF to
be detected via the paradoxical decrease in local blood
deoxyhaemoglobin concentration which occurs with
an increase in CBF; the change in deoxyhaemoglobin
concentration alters the magnetic properties of blood
and this change is detected using MRI. Technically
demanding to perform, the technique is conceptually
very simple: EEG data is collected while a subject
is scanned very frequently; images following spikes
or during seizures are compared with images at ‘rest’
using voxel-based statistics, resulting in an image
of significant change in CBF. Limitations of the
method include movement artefact, although this may
be compensated for by image coregistration, and the
fact that it is impracticable for a patient to lie for
hours in an MRI scanner awaiting the onset of a
seizure. Most studies to date have used spike-triggered
imaging; that is, an EEG spike is used as the cue
to scan; current developments allow continuous EEG
recording and continuous scanning, allowing more
subtle EEG changes to also be included within the data
analysis, potentially improving the sensitivity.
The first study successfully localizing seizure
onset with fMRI was undertaken in an unusual
patient who had frequent partial seizures which
were clinically obvious and which did not result in
excessive movement artefact17, hence simultaneous
EEG recording was not required. Such patients are
exceptionally unusual and although such studies are
of very great interest, this approach is not likely to
be clinically useful for most patients. In general, most
subjects do not have seizures which are compatible
with continuing an MRI study. Therefore the approach
usually taken has been to map with fMRI the correlates
of interictal epileptiform activity on the EEG. One
approach has been to look for brain regions which
show marked changes in CBF during an interictal
fMRI study and attempt to correlate these regions with
EEG recorded on a separate occasion18. Although
this technique is inherently relatively simple, the
lack of simultaneous EEG renders the findings open
to misinterpretation. Nonetheless, this technique has
been used to demonstrate activation of the thalamus
correlated in time with activation of a frontal seizure
focus in a patient with frequent partial seizures,
indicating activation of a neural network19.
Simultaneous EEG during fMRI image acquisition
is technically extremely demanding20 and is still
in development, though is highly promising. fMRI-
compatible EEG equipment is now available commer-
cially and this approach is likely to become widely
used in the near future. Issues with regard to safety
and artefacts from the patient’s pulse and due to the
scanner itself21–24 have been largely overcome. In
24 studies of 10 patients selected for spike-triggered
fMRI study on the basis of frequent interictal spikes,
six of the 10 patients showed reproducible focal
changes, which occurred in close spatial relationship
to the maximum of the epileptiform discharges in
the concurrent EEG; no reproducible signal changes
were observed in the remaining four patients25.
In a separate study, 11 patients in pre-surgical
evaluation underwent spike-triggered fMRI. Seven
showed focal signal changes; six of these patients
142 M. P. Richardson
had intracranial electrode recording and this site of
seizure onset was confirmed in five26. A further
spike-triggered study showed focal signal change in
nine of 10 patients27. Further studies are required to
optimize the method and to determine the sensitivity
specificity of the technique for location of the seizure
focus in larger, unselected groups of patients. In
particular, defining the irritative zone of the cortex
(that generates interictal spikes) and its relationship
with the epileptogenic zone (that gives rise to seizures)
in patients in whom surgical treatment is being
considered will need critical evaluation. An important
application of the technique may be in constraining
the solution to the ‘inverse problem’ inherent in EEG
source analysis.
Localization and lateralization of cognitive
function
In the context of pre-surgical planning, the identifica-
tion of cortex necessary for important cognitive and
motor functions is essential to limit operative mor-
bidity. Intraoperative electrocorticography, recording
from and stimulation of invasive implanted electrodes
and the intracarotid sodium amytal test (Wada test)
are all frequently used for this purpose. All have the
limitations of risk and restricted sampling. Functional
imaging, especially with fMRI, holds the promise to
permit detailed mapping studies to be performed on an
individual basis pre-operatively. A preliminary study
showed that the BOLD signal contrast obtained in
simple tests of language and motor function was very
similar between subjects with epilepsy and normal
controls, demonstrating the feasibility of the technique
in studies of patients with epilepsy28.
Pre-operative assessment of language lateralization
is important in many operative candidates. An
early study29 examined post-operative patients only
and compared the BOLD signal correlates of a
semantic decision task with a pre-operative Wada
test in seven subjects with temporal lobe epilepsy
(TLE); in all cases, using a region-of-interest based
analysis looking only at inferior frontal regions, the
lateralization by fMRI was the same as by the
Wada test. Another early study30 showed that in two
subjects with temporal lobe lesions the pattern of
activation during an auditory comprehension task was
greatly altered anatomically by the presence of the
lesion. A much larger study attempted to correlate
the Wada test and fMRI assessment of language
laterality, using a laterality index for the Wada test (a
continuous variable) and a laterality index from fMRI
calculated as an asymmetry in the voxels activated
in each hemisphere by a semantic decision task31.
The correlation was extremely strong (r = 0.96,
P< 0.0001) and all subjects were classified to the
same laterality by the two tests. A similar approach
has also been used in children32. Using a different
activation paradigm (word generation), a study of 15
subjects failed to show a convincing correlation with
the Wada test33. An interesting approach matched
a group of left TLE subjects to a group of right
TLE patients, in terms of handedness, verbal memory
scores and approximate number of voxels activated
by a semantic decision task34; comparison of the two
groups showed that the right TLE group activated
the left mesial temporal lobe, whereas the left TLE
group did not. A further study mostly in patients
with lateralized lesions but not epilepsy35 examined
a range of activation tasks to find those most strongly
correlated with the Wada test; despite the conflicting
data above, this was found to be a verb generation task.
Patients undergoing pre-surgical assessment may
be evaluated using the Wada test; this is undertaken
primarily to reveal the ability of each hemisphere
to sustain verbal memory, rather than to determine
language dominance. Tasks which reliably activate the
mesial temporal structures in normal subjects using
fMRI have been developed only relatively recently
and widespread application in epilepsy is awaited. An
early study employed a complex visual encoding task
known to activate both mesial temporal regions in
normal patients. In patients with TLE, the activation
was asymmetric and strongly correlated with the
results of Wada testing of memory36. Another study
used a verbal memory encoding and retrieval paradigm
to compare patients with left TLE against normals37;
normals activated parahippocampal regions, right
more than left, during retrieval; this pattern was less
marked in the patients, but in the patient group a left
frontal region participated. The authors interpret this
as a difference in pattern of activation but overlook the
vast difference in performance between the patient and
normal control groups—the patients recalled with far
less accuracy (P < 0.0007).
There are many caveats in using fMRI to map
cortical function in patients with epilepsy. Firstly,
there are many important differences in the method-
ological approaches taken. There is no single ‘test’
which identifies, for example, ‘language cortex’. Most
studies employ a paradigm in which one functional
state is compared with another, e.g. the BOLD signal
during a task requiring attention to the phonological
attributes of a word (its sound) is compared with the
BOLD signal during a very similar task requiring
attention to the semantic attributes of a word
(its meaning), hopefully isolating the brain regions
associated with meaning. A different language-related
task might activate a different set of brain regions,
however. Secondly, it cannot be assumed that these
regions include all of those necessary and responsible
Functional imaging in epilepsy 143
for language; neither can it be determined which of
these regions are sufficient for language production.
Thirdly, the many differences in scanner field strength,
acquisition parameters, paradigm design and image
analysis are so variable between studies that compa-
rability is almost impossible. Hence, although fMRI
as an approach to brain mapping in normal subjects is
very well established, the need for an interpretation of
the imaging result which can then adequately inform
resective surgery has limited the application of this
technique in epilepsy to date.
MAGNETIC RESONANCE SPECTROSCOPY
Proton (1H) spectroscopy
In epilepsy studies in vivo, the principal signals of in-
terest have been those from N-acetyl aspartate (NAA),
creatine+ phosphocreatine (Cr), choline-containing
compounds (Cho), and lactate (Lac). There is evidence
that NAA is located primarily within neurones and
precursor cells and a reduction of NAA signal is
usually regarded as indicating loss or dysfunction of
neurones. Cr and Cho are found both in neurones
and in glial cells, and cell studies suggest that they
are present at much higher concentrations in glia than
neurones38.
Proton (1H) MRS in TLE
In TLE caused by hippocampal sclerosis, the essential
finding has been a reduction of NAA and an
increase of choline-containing compounds (Cho),
creatine+ phosphocreatine (Cr), reflecting neuronal
loss or dysfunction and astrocytosis39, 40. The mean
NAA/Cho+Cr ratios were significantly less in
patients with epilepsy than in control subjects, and
were more marked on the ipsilateral than contralateral
side. At an individual level, a reduced NAA/Cho+Cr
ratio on the side of the focus was found in 88%, though
40% had bilateral abnormalities. Similar findings have
been made in children with TLE41: an abnormal
NAA/(Cho+Cr) ratio was found in 75%, bilateral
in 45%, allowing correct lateralization of the seizure
focus in 55%.
The hippocampus occupies only a small volume of
the voxel used for these analyses, hence the reduction
of NAA was such that the abnormality could not
be confined to the hippocampus. This finding is
analogous with the findings of 18FDG PET and blood
flow SPECT studies described below, which have
found a much wider area of functional abnormality
beyond the bounds of the structurally abnormal
sclerotic hippocampus. Comparisons of quantitative
MRS and 18FDG PET showed a correlation between
the NAA/Cho+Cr ratio detected on MRS and
the degree of hypometabolism in TLE42; a similar
correlation was found between SPECT hypoperfusion
and abnormalities demonstrated by 1H MRS43. After
successful temporal lobe resection, there is a tendency
for the NAA in the contralateral medial temporal lobe
to normalize44.
The studies above examined single large voxels;
these preclude the accurate delineation of the ori-
gin of the abnormal signals. Magnetic resonance
spectroscopic imaging (MRSI) has the advantage of
greater anatomical information, but at the expense of
greater susceptibility to artefacts. Localized reductions
of NAA/Cho in 53 patients with temporal lobe
epilepsy, unilateral in 34 and bilateral in 19, have
been reported with this technique45. In 10 patients
with temporal lobe epilepsy and five controls, the
left–right asymmetry of NAA/Cr ratios was found
to be significantly different from controls in all
cases46. In a large series of 100 patients with temporal
lobe epilepsy, strong concordance was found between
EEG, MRSI, and hippocampal volumetry47.
A further methodological advance has been imaging
at very high field strength, using high-resolution single
slice MRSI obtained at 4.1 Tesla, and mapping MRS
data onto the equivalent MRI slice48. This approach
allowed a clear anatomical delineation of the origin
of the abnormal signals: a reduced NAA/Cr ratio
was found in the epileptogenic hippocampus in all
of 10 patients with TLE. Four also had abnormalities
in the contralateral hippocampus and in two of
these invasive EEG recordings demonstrated bilateral
independent seizure onset. Furthermore, in the three
patients with normal MRI the pathological specimen
showed gliosis and minimal neuronal loss, suggesting
that this technique may be useful for the in vivo
identification of subtle pathology. Interestingly, in
another study NAA was not reduced in the hippocampi
of patients with neocortical epilepsy49, implying that
hippocampal dysfunction is not found in neocortical
epilepsy.
Temporal lobe MRS data may correlate with
cognitive problems: patients who had right temporal
resections and who had abnormalities of MRS in the
left temporal lobe had some verbal memory deficits50.
Furthermore, abnormalities of proton MRS in the left
temporal lobe were associated with a loss of verbal
cognitive functions, and abnormalities on the right
were associated with impaired non-verbal functions51.
A post-ictal rise in lactate has been shown using 1H
MRSI in the ipsilateral temporal lobe in patients with
unilateral temporal lobe epilepsy, and also confined
to one side in patients who appeared to have bilateral
TLE52. An elevation of cerebral lactate has been noted
during and for a few hours after complex partial
seizures, with no change in NAA. In contrast, there
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were no changes following absences53.
Neurotransmitters
GABA is the principal inhibitory neurotransmitter and
glutamate the principal excitatory neurotransmitter
in human brain. Many hypotheses explaining the
origin of epilepsy implicate an imbalance between
GABA-mediated inhibition and glutamate-mediated
excitation. Proton (1H) MRS, using spectral editing,
can identify cerebral GABA in vivo and estimate the
rise in cerebral GABA concentrations that occurs after
administration of vigabatrin54, 55, gabapentin56 and
topiramate.
Measurement of glutamate is technically very
demanding because of the overlap of several spectral
peaks; important recent methodological advances now
set the stage for the measurement of GABA and
glutamate regionally in a variety of syndromes,
permitting a new approach to the phenomenological
description of epileptic syndromes.
31P spectroscopy
Cerebral metabolites detectable with 31P MRS in-
clude adenosine triphosphate (ATP), phosphomo-
noesters (PME), phosphodiesters (PDE), phosphocre-
atine (PCr), and inorganic phosphate (Pi). At neutral
pH, Pi exists principally as HPO4 and H2PO4. The
chemical shift of 31P in these two molecules differs by
approximately 2.4 ppm, but rapid exchange between
the two forms results in only a single MR spectral
peak being detected. The resonance frequency of
the peak is dependent on the pH of the tissue;
this is reflected in the effective chemical shift of
Pi and is measurable in vivo. In eight patients with
TLE, no significant asymmetries between ipsilateral
and contralateral temporal lobes of ATP, PCr or
PDE concentrations were found, but in seven of the
eight patients, the temporal lobe ipsilateral to the
focus had increased pH and, in all eight, increased
Pi57; this finding was replicated58. If confirmed, the
neurobiological significance of an increase in pH
associated with a seizure focus is not clear.
Conclusion
Over the last decade MRS has advanced as a non-
invasive tool for investigating cerebral metabolism.
The rapid developments now being made in MR hard-
ware and software may enable parametric imaging of
the cerebral concentrations of these compounds, and
this may have important consequences for the non-
invasive investigation and the medical and surgical
treatment of patients with epilepsy.
SINGLE PHOTON EMISSION COMPUTERIZED
TOMOGRAPHY (SPECT)
Single photon emission computerized tomography is
principally used, in the investigation of the epilepsies,
to image the distribution of CBF. In addition, there
have been a few studies of specific receptors in the
brain.
Cerebral blood flow tracers
SPECT may be used to indicate relative regional cere-
bral blood flow (rCBF) using a variety of radiotrac-
ers, currently usually 99mTc-hexamethylpropylene-
amine-oxime (HMPAO) or 99mTc-ethyl cysteinate
dimer (ECD). Investigations using these methods
began before the era of high-resolution MRI, when a
considerably higher proportion of patients would have
been found normal with other imaging modalities;
comparisons between imaging modalities in this
substantial older literature now need cautious re-
interpretation. Insufficient data exist to determine
whether ECD is superior to HMPAO; ECD does not
require to be reconstituted at the bedside, hence it is
likely ECD can be injected sooner after the seizure
onset in ictal studies. HMPAO is taken up rapidly into
the brain (70% within 1 minute); the image is then
stable for about 6 hours since HMPAO reacts with
glutathione and becomes trapped. ECD and HMPAO
have slightly different uptake patterns.
One of the earliest studies revealed the essential
phenomena of increased local blood flow in the ictal
state and reduced flow interictally59. The particular
value of regional hyperperfusion during ictal studies
was soon amply confirmed60, both in secondary
generalized, as well as partial, seizures61, 62. In the
early MRI era, and with EEG used as a gold standard,
interictal SPECT correlated with EEG in 75% and
with MRI in only 61%, leading to the conclusion
that, with these technologies, SPECT was superior
to MRI for focus localization63. With rapid progress
in MRI technology, interictal SPECT was recognized
to be inferior to MRI for focus localization64.
Further studies revealed the paradoxical and clinically
limiting observations of interictal diffuse, multifocal
and bilateral hypoperfusion, or focal hyperperfusion,
as well as focal hypoperfusion65, 66 in addition to
limited concordance with EEG67–71. Five hundred
and thirty-nine patients reported in the literature with
interictal SPECT have been reviewed72. Two hundred
and ninety-one patients were localized by SPECT
to the temporal lobe, 65 to extra-temporal locations
and 183 were unlocalized. Seventy-nine percent
showed concordance of the interictal SPECT and EEG
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localization. Interictal SPECT localization did not
contribute to prediction of good seizure outcome73.
Further investigations have confirmed the greater
sensitivity of ictal SPECT: interictal studies were
localizing in 46–76% compared to 75–97% of ictal
studies74–82. In extratemporal seizures ictal SPECT
studies localized the focus in 92%, compared to 46%
for post-ictal studies and interictal SPECT was of
little value82. Ictal scans may be especially useful in
the evaluation of patients with extra-temporal seizures
with normal MRI, localizing the seizure focus in
10 of 12 patients in one series and in 20 of 22 in
another83, 84. The technical difficulties of ictal studies
were somewhat assuaged by the finding that early
post-ictal SPECT was more sensitive than interictal
SPECT82, 85, 86.
Recently, a highly promising semi-automated com-
puterized technique allowing interictal studies to be
‘subtracted’ from coregistered ictal studies has been
developed (Fig. 1)87–89. The automated technique
permitted more than twice as many seizure foci to be
located as a traditional ‘side-by-side’ qualitative visual
comparison. Furthermore, those patients in which the
ictal onset zone as defined by the automated technique
was resected were more likely to have an excellent
outcome than those patients in which the resection did
not include the ictal zone identified in this manner. The
resection of seizure foci located with the traditional
‘side-by-side’ qualitative comparison did not predict
outcome.
In conclusion, interictal SPECT alone is of little
value in the current era; ictal SPECT may be helpful in
patients with normal imaging, especially in temporal
lobe epilepsy; the experience with ictal SPECT in
extra-temporal seizure disorders is still limited, though
promising. The coregistration of interictal and ictal
SPECT images, to result in an ‘ictal difference image’
that may be coregistered with an individual’s MRI
enhances the accuracy of data interpretation and is
likely to become the most useful SPECT technique in
pre-surgical evaluation.
Some regional abnormalities in blood flow SPECT
were possibly related to neuropsychological de-
fects90, 91. Serial SPECT studies in the interictal,
ictal and immediate post-ictal states were performed
in 12 patients with refractory TLE to define the
patterns and duration of peri-ictal CBF changes.
Visual and quantitative analysis showed a constant
pattern of unilateral global increases in temporal lobe
perfusion during seizures which suddenly switched to
a pattern of relative mesial temporal (hippocampal)
hyperperfusion and lateral temporal hypoperfusion
in the immediate post-ictal period78, 92. ‘Reversed’
crossed cerebellar diaschisis was observed in ictal
studies, with cerebellar hyperperfusion contralateral
to the cerebral focus93. Focal hyperperfusion was
demonstrated in epilepsia partialis continua with
normal EEG94. In temporal lobe epilepsy, ictal
dystonia was associated with a relative increase in
perfusion of the basal ganglia opposite the dystonic
limb. Additionally, slight increases in cortical blood
flow on the side opposite the direction of version
were associated with head-turning, irrespective of the
side of seizure focus84, 95. The latter study revealed
asymmetric tonic posturing, contralateral head and
eye deviation and unilateral clonic jerking were
associated with an ictal increase in CBF in the
frontocentral, medial frontal or dorsolateral areas.
Different perfusion patterns were seen in different
aetiologies of TLE with ictal SPECT96.
Benzodiazepine receptors
123I-Ro16-0154 (123I-iomazenil) was shown to have
intracerebral retention parallel to the known distribu-
tion of benzodiazepine receptors (BZR) in man97. In
comparative studies of HMPAO and 123I-iomazenil
SPECT, most subjects show concordant regions of
reduced uptake with both tracers; some studies show
a small difference in sensitivity, a more marked
reduction or a more restricted area of reduced
tracer uptake with 123I-iomazenil98–103. These studies
suggest little advantage in imaging BZR over blood
flow. However, in a patient with focal epilepsy due
to MCD a marked focal decrease in 123I-iomazenil
uptake was seen in this area but normal HMPAO up-
take104. Some animal evidence suggests BZR imaging
should be clinically useful. In hippocampal kindled
rabbits, in vivo double tracer autoradiography using
125I-Iomazenil and 99mTc-HMPAO, 125I-Iomazenil
accumulation was more markedly and extensively
decreased than 99mTc-HMPAO accumulation105.
The reason for the disappointing results of clin-
ical application of SPECT BZR imaging may be
methodological. A single image of iomazenil binding,
without any kinetic modelling, may be seriously
confounded by changes in regional blood flow106–109.
Hence, without performing multiple scans in the same
session coupled with measurements of radiotracer
in blood, 123I-iomazenil SPECT may actually be
mainly indicating regional blood flow rather than BZR
density.
POSITRON EMISSION TOMOGRAPHY (PET)
STUDIES OF CEREBRAL GLUCOSE
METABOLISM
18FDG has been used with PET to measure regional
cerebral metabolic rate for glucose (rCMRgluc). Most
human studies have been of the interictal state; the
146 M. P. Richardson
Fig. 1: Pre-operative subtraction ictal SPECT coregistered with MRI (SISCOM) images (A and C) and post-operative coregistered
MRI (B and D). A and B, complete excision of neocortical region underlying SISCOM focus. C and D, non-excision of neocortical
region underlying SISCOM focus. In the accompanying paper (O’Brien et al. Subtraction peri-ictal SPECT is predictive of
extratemporal epilepsy surgery outcome. Neurology 2000; 55: 1668–1677) it was shown that resection of the SISCOM focus was
significantly more likely to result in a good post-operative outcome. Copyright 2000 AAN Enterprises, Inc. Used with permission.
hallmark in localization-related epilepsy has been a
regional decrease in rCMRgluc interictally, although a
study of drug-naive patients found interictal increased
rCMRgluc110. Several studies of 18FDG PET have
found a 60–90% incidence of hypometabolism in
the temporal lobe interictally in adults and children
with TLE 64, 111–119. Surgical ECoG findings have
confirmed the epileptogenic nature of regions of in-
terictal hypometabolism120. The hypometabolic zone
is frequently extensive and, particularly in TLE, may
involve regions outside the ictal onset area; in patients
with a unilateral temporal lobe focus the asymmetry
of metabolism may be more pronounced in the
lateral temporal cortex than in the mesial part of the
temporal lobe; indeed, in most cortical and subcortical
regions on the side of the epileptic focus, glucose
consumption rate is lower than in the contralateral
region or than in controls119, 121. A well-localized
region of decreased glucose metabolism is found less
frequently in extratemporal seizure disorders than in
TLE, usually in association with a concordant MRI
abnormality122, 123.
Although regional hypometabolism may be detected
in patients with lesions or normal MRI, the clinical
utility of such a finding is controversial. In patients
judged to have TLE, the presence of temporal
lobe hypometabolism was associated with a better
outcome after ipsilateral temporal lobectomy than in
patients without hypometabolism124; another study
found the degree of lateral temporal (rather than
mesial temporal) hypometabolism to be a predictor
of good outcome125; a further study found the
opposite (mesial temporal metabolism was the better
predictor)126; and yet another study found that even
with no hypometabolic region, good outcome could be
obtained127. A false localizing PET result for lobe of
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onset has been reported in as many as 36%, limiting
the usefulness of such data128. However, in patients
with concordant findings with non-invasive EEG and
18FDG PET, depth studies were never discordant,
suggesting 18FDG PET might obviate the need for
depth recording129.
In more recent comparative studies of MRI and
PET, although the yield of abnormalities with 18FDG
PET may be high, usually these abnormalities are
concordant with an MRI abnormality, suggesting
18FDG PET does not provide clinically useful data
if the MRI findings are definite, but may have some
additional sensitivity118, 123, 130, 131.
The superiority of quantitative over visual in-
terpretation of 18FDG PET in TLE has been
demonstrated132. It may be possible to improve the
delineation of the hypometabolic zone in TLE by
performing activation tasks during the scan, such
as ‘emotional speech’, which increase the contrast
between normal and abnormal regions in the temporal
lobe133.
In paediatric practice 18FDG PET may have
a more valuable role. 18FDG PET has enabled
a characterization of the functional abnormalities
in children with severe epilepsies, in some cases
enabling remarkably effective surgical intervention
in children with normal MRI134. In eight children
with intractable neonatal onset seizures, interictal
PET revealed unilateral diffuse hypometabolism in
three, leading to highly effective hemispherectomy.
In one child, ictal PET showed hypermetabolism
in the left frontal cortex, left striatum, and right
cerebellum; again, a large resection was immensely
successful135. In 13 children with infantile spasms
of undetermined cause, unilateral hypometabolism
involving the parieto-occipito-temporal region was
found in five; MRI was normal in four of these.
Four of these five infants underwent surgical removal
of the cortical focus with seizure-free outcome;
pathological examination of resected tissue in each
showed microscopic cortical dysplasia136.
In summary, although 18FDG PET has been
useful in the past for detecting a seizure focus
possibly amenable to surgery, the improvements in
MRI technology have rendered such routine clinical
investigation superfluous in the majority of patients.
However, in selected MRI normal patients, particu-
larly children, a place remains for evaluation with
18FDG PET, with the caveat that the hypometabolic
region may be found to be more extensive than the
ictal onset zone. However, 18FDG PET has provided
valuable information about metabolic abnormalities
in an extensive cortical-subcortical network and an
insight into patterns of ictal metabolism.
Despite reservations about the current place of
18FDG PET in clinical investigation, this technique
has yielded interesting information relating to the neu-
robiology of seizure disorders. Some differences exist
in the metabolic patterns associated with different
aetiologies of TLE: patients with HS have the lowest
18FDG uptake in the entire temporal lobe, followed by
patients with lateral temporal seizure origin. Patients
with tumours in the mesiobasal temporal lobe show
only a slight decrease of glucose metabolism137. The
comparison of metabolic patterns on 18FDG PET with
video EEG telemetry in 48 patients revealed patients
with frontal hypometabolism alone had shorter ictal
and post-ictal durations; auras were more likely to
be present in patients with temporal hypometabolism
alone; other metabolic patterns did not predict specific
ictal clinical features138. Hypometabolism of basal
ganglia and thalamus has been observed in patients
with TLE of both limbic and neocortical origin139, 140.
Relative hypometabolism of the left hemisphere corre-
lated with lower cognitive performance in 13 unilateral
TLE patients. Hypometabolism of the left lateral
temporal lobe and thalamus independently correlated
with verbal memory difficulties141. Patients with
localization-related epilepsy had bilateral cerebellar
hypometabolism that was not fully explained by treat-
ment with phenytoin132. The metabolic consequences
of successful surgery have been investigated. After
selective amygdalo-hippocampectomy in patients with
HS there was an increase of rCMRgluc in the
ipsilateral and also the contralateral hemisphere142.
18FDG PET has been employed to examine patients
with MCD. Glucose metabolism similar to normal
cortex has been detected using 18FDG PET in the
ectopic neurones in band heterotopia143, 144 and in
heterotopic nodules and displaced grey matter145, 146.
Of 17 patients with MCD, 15 had abnormal PET
findings, consisting of focal hypometabolism in nine
patients and displaced metabolic activity of normal
grey matter, reflecting underlying grey matter hetero-
topia, in six. All 15 patients had MRI abnormalities147.
Four of eight children with hemimegalencephaly had
regions of reduced metabolism in the unaffected hemi-
sphere148. Multiple regions of focal hypometabolism
have been demonstrated in patients with tuberous
sclerosis149. A study including both patients with
acquired lesions and congenital abnormalities such as
tuberous sclerosis and agenesis of the corpus callosum
showed regions of decreased metabolism which were
more extensive than the MRI lesions in some cases150.
Attempts have been made to determine the functional
capacity of dysgenetic regions. A medical student with
extensive unilateral heterotopic grey matter underwent
a resting 18FDG PET in which metabolic activity
similar to normal cortex was seen in the heterotopia;
during a second scan the patient undertook a verbal
fluency task which resulted in a slight increase in the
metabolic rate in the heterotopic region151.
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A small number of studies have examined ictal
metabolic patterns. By chance, 18 children undergoing
18FDG PET had seizures during the 18FDG uptake pe-
riod. Three major metabolic patterns were determined
based on degree and type of subcortical involvement.
Nine children had asymmetric glucose metabolism
of striatum and thalamus, usually involving unilat-
eral cortical hypermetabolism and crossed cerebel-
lar hypermetabolism. Five children had symmetric
metabolic abnormalities of striatum and thalamus;
this pattern was accompanied by hippocampal or
insular cortex hypermetabolism, diffuse neocortical
hypometabolism, and absence of any cerebellar abnor-
mality. Four children had hypermetabolism restricted
to cerebral cortex152. Focal hypermetabolism has been
noted in EPC153. Hypometabolism is accentuated after
a seizure and may not return to the interictal state for
more than 24 hours154.
POSITRON EMISSION TOMOGRAPHY
STUDIES OF SPECIFIC LIGANDS
Benzodiazepine receptors
The benzodiazepine receptor ligand 11C-flumazenil
binds to the central benzodiazepine receptor (cBZR)
which is present on the majority of GABAA receptors.
Hence, 11C-flumazenil PET can provide images
indexing GABAA receptor density. The first such
study showed focal decreased BZR density in cortical
seizure foci155 which were more closely localized
than reduction in glucose metabolism as indicated
by 18FDG PET (Fig. 2)156. The reduction in BZR
density in the epileptogenic hippocampus has been
further confirmed in other studies9, 157, 158. Recent
studies have shown marked increase in sensitivity
through techniques for correction of partial volume
effects in patients with hippocampal sclerosis8 and
precise correlation of BZR binding measured by 11C-
flumazenil PET and by ex vivo autoradiography of
resected specimens in the same patients159. Epileptic
foci outside the hippocampus have not been systemat-
ically studied, although small numbers of cases have
been described with focal decrease in receptor density
(Fig. 3)155. In the great majority of these studies, PET
abnormalities were concordant with known MRI ab-
normalities. In patients with malformations of cortical
development, multiple areas of abnormal BZR binding
were frequently detected, often remote from the MRI-
defined abnormality10; these abnormalities were not
explained by unsuspected structural abnormalities12.
It remains to be established if such findings correlate
with poor surgical outcome.
Quantification of PET data requires a volume-of-
interest based approach, and in view of the size of
the hippocampus and the limited spatial resolution of
PET, correction for partial volume effects3, 160. Cor-
rection of partial volume effects resulted in increased
sensitivity of 11C-flumazenil PET in detection of
unilateral hippocampal sclerosis8 and also identified
bilateral hippocampal abnormalities of BZR in one
third of patients who appeared to have unilateral HS
on MRI161. Further, after correction of partial volume
effects, 11C-flumazenil binding in vivo in patients with
HS undergoing surgical resection was reduced by a
mean of 38%, indicating that the loss of binding was
not simply due to hippocampal atrophy8.
The place of 11C-flumazenil PET in the clinical
investigation of patients with refractory localization-
related and unremarkable high quality MRI has
been little investigated. In six patients with frontal
lobe epilepsy, five with normal MRI, reduction in
cBZR binding was demonstrated with 11C-flumazenil
PET, which was consistent with clinical and EEG
data162. Using an automated, objective technique for
comparing individual patient scans with a normal
control group, 13 of 18 patients with neocortical
localization-related epilepsy and normal MRI had
regional abnormalities of BZR binding; in 10 these
regions had increased BZR binding. In a subgroup
with frontal lobe seizures, 60% had focal BZR
abnormalities concordant with clinical and EEG
data163. Greater reduction of 11C-flumazenil binding
has been reported in patients with frequent seizures
compared to those with less frequent seizures164. This
finding has not been confirmed by other studies.
In a clinical series of 100 patients with partial
seizures having pre-surgical evaluation, 94% of those
with TLE had an abnormality of 11C-flumazenil
PET detected, as did 50% of those with other
forms of partial epilepsy; 81% of abnormalities
found using 11C-flumazenil PET were concordant
with abnormalities on MRI. 11C-flumazenil PET was
useful in the identification of bilateral temporal lobe
pathology165. Currently, there is insufficient data to
support the routine clinical use of BZR PET imaging,
though it is a technique showing great promise in the
evaluation of MRI-normal subjects.
Primary generalized epilepsy has been much less
studied than focal epilepsy. Diagnostic classification
is often difficult; this may explain the contradic-
tory results noted in different studies. There is
increasing evidence that the fundamental abnormality
underlying primary generalized epilepsy appears to
lie outside the GABAA system166, so abnormalities
of 11C-flumazenil binding might not be expected.
Childhood and juvenile absence epilepsy patients were
shown to have normal interictal 11C-flumazenil bind-
ing167; other primary generalized epilepsy patients
have been shown to be not significantly different from
normals168 or to have increased receptor density in
the cerebellar nuclei and decreased receptor density
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Fig. 2: The top row shows three sections through a T1-weighted MRI of a subject with onset of seizures in the right temporal
lobe (left side of the figure). 1T MRI was normal. The second row shows a coregistered 18FDG PET; extensive right temporal
hypometabolism is demonstrated. However, the bottom row depicts 11C-flumazenil PET from the same subject; the region of
reduced flumazenil binding is much more restricted, confined only to the right mesial temporal structures. From: Szelies et al.
MRI-Guided Flumazenil- and FDG-PET in Temporal Lobe Epilepsy Neuroimage 1996: 3; 109–118 (Fig. 3(a)). Copyright Academic
Press 1996, used with permission.
in the thalamus169. This latter finding is intriguing,
pointing to abnormalities outside the thalamocortical
loop usually regarded as the substrate of generalized
seizure discharges170; the finding has not yet been
replicated in man or confirmed in animal studies.
Further work is needed to clarify the findings in well-
defined diagnostic groups.
The effects of drugs on BZR binding in man have
not been widely examined using 11C-flumazenil PET.
Treatment with sodium valproate was associated with
a significant reduction in receptor density in a cross-
sectional study of patients with childhood and juvenile
absence epilepsy167, suggesting a possible mechanism
of therapeutic action.
Absence seizures were induced by hyperventilation
in susceptible volunteers during the course of a study.
Comparing the 11C-flumazenil binding with that in a
scan without seizure provocation in the patients, with
scans of normals and with computer simulations of the
effects of changes in blood flow or receptor binding
due to seizures, alterations of benzodiazepine receptor
characteristics during absences were not detected171.
Opioid receptors
The rationale for employing opiate receptor ligands
is the demonstration that endogenous opioids are
released following partial and generalized tonic–
clonic seizures and contribute to the post-ictal rise in
seizure threshold172. An increase in µ-agonist 11C-
carfentanil binding to µ-receptors in lateral temporal
neocortex in areas which also showed reduced glucose
metabolism has been shown173. This may be a
tonic antiepileptic system that serves to limit the
spread of electrical activity. The increase in 11C-
carfentanil binding to lateral temporal neocortex was
confirmed and reduced binding to the amygdala was
noted174, though this may be an artefact of partial
volume effects. Using 11C-diprenorphine, which binds
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Fig. 3: On the left of the figure is shown sections from a T1-weighted MRI of a patient with a right anterior temporal DNET
(above) and coregistered 11C-flumazenil PET from the same subject. Using statistical parametric mapping (SPM), an objective
and automated means for comparing images, the right side of the figure shows (in blue rendered onto the MRI) the region having
a significantly reduced flumazenil binding compared with 24 normal controls.
with similar affinities to µ, κ and δ subtypes
of opioid receptors, there were no abnormalities
of binding of 11C-diprenorphine in the temporal
lobe or elsewhere174, 175. In addition, there was no
overall asymmetry of binding of 18F-cycloFOXY,
which binds to µ and κ receptors in patients with
TLE176. The explanation of these findings is not
clear, although either an upregulation of µ receptors
and reduction of number or affinity of κ receptors,
or upregulation of µ receptors and occupation of κ
receptors by an endogenous opioid ligand would fit the
evidence.
Dynamic ictal studies of opioid receptors have
been carried out in patients with reading epilepsy,
using 11C-diprenorphine. In order to localize dynamic
changes of opioid neurotransmission associated with
partial seizures and higher cognitive function, release
of endogenous opioids in patients with reading
epilepsy was compared with that in healthy volun-
teers177. Reading-induced seizures were associated
with reduced 11C-diprenorphine binding to opioid
receptors in the left parieto-temporo-occipital cortex
and to a lesser extent the left middle temporal gyrus
and the posterior parieto-occipital junction. These
data gave evidence for localized endogenous opioid
peptide release during seizures induced by reading and
demonstrate the potential of PET to image release of
specific neurotransmitters in response to brain activity
in specific cerebral areas in vivo.
Other ligands
MAO-B receptors
Deprenyl binds to monoamineoxidase (MAO)-B
receptors, which are mainly located on astrocytes.
In nine patients with TLE 11C-deuterium deprenyl
binding was increased in the epileptogenic temporal
lobe, possibly reflecting gliosis178.
NMDA receptors
11C-(S)-[N-methyl]ketamine binds to the NMDA
receptor, and is thus of interest in studies of epilepsy.
In eight patients with medial TLE there was a
reduction in tracer binding potential that paralleled
hypometabolism. It is not clear, however, whether the
reduction was due to reduced perfusion, loss of tissue
or reduction of receptor binding179 and further work is
needed to clarify this.
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Serotoninergic neurones
Increased concentrations of serotonin and serotonin-
immunoreactivity have been reported in resected
human epileptic cortex. Alpha-[11C]methyl-L-
tryptophan ([11C]AMT) is a marker for serotonin
synthesis. In children with tuberous sclerosis, uptake
was increased in some tubers that appeared to be
the sites of seizure onset. Other tubers showed
decreased uptake. In contrast, 18FDG PET showed
hypometabolism in all tubers. This study suggests that
[11C]AMT PET may be useful to detect epileptogenic
foci, in patients with tuberous sclerosis, and possibly
other forms of cerebral malformation180.
Histamine receptors
An increase of H1 receptors, visualized with PET and
11C-doxepin in epileptic foci, that also show reduced
interictal glucose metabolism, has been reported181.
It has been suggested that this finding is compatible
with an increase of µ opioid receptors. It is not certain,
however, how specific this tracer is for H1 receptors.
Peripheral benzodiazepine receptors
The peripheral benzodiazepine receptor ligand,
11C-PK11195, labels macrophages and activated
microglia, and as such is a marker of inflammatory
responses in the brain. Increased binding has been
demonstrated in Rasmussen’s encephalitis, reflecting
the inflammatory nature of the condition, and is in
contrast to hippocampal sclerosis in which there is no
increased binding182.
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